Edwards Lifesciences Corp (EW) Shares Sold by Trust Department MB Financial Bank N A

Trust Department MB Financial Bank N A lowered its position in Edwards Lifesciences Corp (NYSE:EW) by 24.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,033 shares of the medical research company’s stock after selling 990 shares during the period. Trust Department MB Financial Bank N A’s holdings in Edwards Lifesciences were worth $342,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in shares of Edwards Lifesciences by 2.0% in the second quarter. Vanguard Group Inc. now owns 20,748,569 shares of the medical research company’s stock worth $2,453,311,000 after acquiring an additional 406,901 shares during the period. Wells Fargo & Company MN grew its holdings in shares of Edwards Lifesciences by 20.2% in the third quarter. Wells Fargo & Company MN now owns 2,548,282 shares of the medical research company’s stock worth $278,553,000 after acquiring an additional 429,022 shares during the period. American Century Companies Inc. grew its holdings in shares of Edwards Lifesciences by 7.0% in the third quarter. American Century Companies Inc. now owns 2,224,010 shares of the medical research company’s stock worth $243,107,000 after acquiring an additional 144,701 shares during the period. Artisan Partners Limited Partnership grew its holdings in shares of Edwards Lifesciences by 12.0% in the third quarter. Artisan Partners Limited Partnership now owns 1,432,428 shares of the medical research company’s stock worth $156,579,000 after acquiring an additional 153,896 shares during the period. Finally, Koch Industries Inc. grew its holdings in shares of Edwards Lifesciences by 28,363.1% in the second quarter. Koch Industries Inc. now owns 1,397,254 shares of the medical research company’s stock worth $1,386,000 after acquiring an additional 1,392,345 shares during the period. 81.61% of the stock is owned by institutional investors.

Shares of Edwards Lifesciences Corp (EW) traded up $0.84 during trading on Tuesday, hitting $120.83. The stock had a trading volume of 1,029,800 shares, compared to its average volume of 1,247,700. Edwards Lifesciences Corp has a fifty-two week low of $86.55 and a fifty-two week high of $121.45. The stock has a market capitalization of $25,810.00, a P/E ratio of 35.13, a price-to-earnings-growth ratio of 1.94 and a beta of 0.51. The company has a quick ratio of 2.76, a current ratio of 3.49 and a debt-to-equity ratio of 0.33.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, October 24th. The medical research company reported $0.84 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.86 by ($0.02). Edwards Lifesciences had a net margin of 22.47% and a return on equity of 27.22%. The business had revenue of $821.50 million during the quarter, compared to analysts’ expectations of $833.85 million. During the same quarter in the previous year, the firm earned $0.68 earnings per share. Edwards Lifesciences’s revenue was up 11.1% on a year-over-year basis. analysts forecast that Edwards Lifesciences Corp will post 3.76 earnings per share for the current year.

Edwards Lifesciences announced that its board has approved a share repurchase program on Thursday, December 7th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the medical research company to repurchase shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s management believes its shares are undervalued.

EW has been the topic of several analyst reports. Zacks Investment Research downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 26th. Barclays reiterated an “equal weight” rating and set a $120.00 target price on shares of Edwards Lifesciences in a research report on Saturday, September 30th. Canaccord Genuity reiterated a “buy” rating and set a $155.00 target price on shares of Edwards Lifesciences in a research report on Sunday, October 8th. Cowen reiterated a “buy” rating and set a $135.00 target price on shares of Edwards Lifesciences in a research report on Thursday, October 12th. Finally, SunTrust Banks set a $124.00 target price on Edwards Lifesciences and gave the company a “buy” rating in a research report on Wednesday, October 25th. Six analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. Edwards Lifesciences currently has an average rating of “Buy” and a consensus price target of $129.57.

In related news, CEO Michael A. Mussallem sold 32,900 shares of the business’s stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $100.93, for a total value of $3,320,597.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the business’s stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $101.12, for a total value of $535,936.00. The disclosure for this sale can be found here. Insiders sold 191,520 shares of company stock worth $20,998,608 over the last 90 days. Company insiders own 2.13% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Week Herald and is the sole property of of Week Herald. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://weekherald.com/2018/01/16/edwards-lifesciences-corp-ew-shares-sold-by-trust-department-mb-financial-bank-n-a.html.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply